Tags: Drug Discovery

announcements

Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.

announcements

New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation

Cross-Sector Collaboration Aimed at Speeding the Development of Potential Therapies That May Protect Brain Cells

announcements

New Funding Supports Blood Test for Early Alzheimer’s

The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.

blog

Inflammation, The Driver of Alzheimer's Disease?

A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.

announcements

Latest Funding Includes Support for Innovative Clinical Trial

The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.

announcements

2016 Annual Report Released

The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.

announcements

ADDF and Science Exchange Launch ADDF ACCESS to Advance Research

New “CRO Finder” Connects Scientists with Specialized Resources

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

announcements

Expanded Partnership Increases Support for Drug Discovery

ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.

announcements

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments

We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.